JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Identification of allograft inflammatory factor-1 suppressing the progression and indicating good prognosis of osteosarcoma

  • 0Department of Orthopedics, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, Hubei Province, P. R. China.
Bmc Musculoskeletal Disorders +

|

March 24, 2024

|

March 24, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Allograft inflammatory factor-1 (AIF1) is a potential biomarker for osteosarcoma progression and prognosis. Lower AIF1 expression correlates with poorer outcomes, suggesting AIF1 as a therapeutic target for osteosarcoma.

Area Of Science

  • Oncology
  • Molecular Biology
  • Genomics

Background

  • Osteosarcoma is a prevalent cancer with incompletely understood mechanisms.
  • Identifying novel biomarkers is crucial for improving osteosarcoma diagnosis and treatment.
  • Allograft inflammatory factor-1 (AIF1) was investigated for its role in osteosarcoma.

Purpose Of The Study

  • To investigate allograft inflammatory factor-1 (AIF1) as a potential biomarker for osteosarcoma progression.
  • To elucidate the molecular mechanisms and prognostic value of AIF1 in osteosarcoma.
  • To explore AIF1's association with survival and its functional role in osteosarcoma.

Main Methods

  • Differential gene expression analysis using public microarray (GEO) and TCGA datasets.
  • Gene Ontology (GO) and KEGG pathway enrichment analyses of differentially expressed genes (DEGs).
  • Construction and visualization of a protein-protein interaction (PPI) network.
  • Survival analysis (OS, MFS) and in vitro experiments to assess AIF1 function.

Main Results

  • Identified 126 DEGs, with AIF1 significantly associated with overall survival (OS) and metastasis-free survival (MFS).
  • AIF1 enrichment in the NF-κB signaling pathway and association with tumor immune invasion.
  • In vitro studies revealed AIF1 underexpression in osteosarcoma cells, with its overexpression attenuating malignant properties and affecting the NF-κB pathway.

Conclusions

  • Differentially expressed genes and hub genes, including AIF1, provide insights into osteosarcoma carcinogenesis.
  • AIF1 serves as a potential prognostic biomarker and therapeutic target for osteosarcoma.
  • Understanding AIF1's role in the NF-κB pathway offers new avenues for osteosarcoma treatment.

Keywords: